A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of Pf-04447943 On Qtc Interval In Healthy Adult Subjects

Trial Profile

A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of Pf-04447943 On Qtc Interval In Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs PF 4447943 (Primary) ; Moxifloxacin
  • Indications Sickle cell anaemia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top